Study finds distinct immune landscape associated with African ancestry in multiple myeloma
Andrea Clement
Conceptual illustration of multiple myeloma cells in the bloodstream. (iStock.com)
Largest analysis of its kind identifies more immune cells equipped to attack tumors and less innate inflammation in the bone marrow.
Researchers at Winship Cancer Institute of Emory University and collaborating institutions have identified differences in the bone marrow immune environment of patients with multiple myeloma that are associated with African genetic ancestry. The findings could help scientists better understand the disease's unequal burden and explore how a patient's immune environment might influence treatment.
The study, published in Blood, analyzed samples and clinical data from 320 patients with newly diagnosed multiple myeloma and information from 1.4 million individual cells. It is the first and largest study to examine how African genetic ancestry relates to the immune cells in the bone marrow, where multiple myeloma begins.
Manoj Bhasin, PhD, MS
Manoj Bhasin, PhD, MS, a senior and corresponding author of the study, is a member of the Cancer Immunology Research Program at Winship.
"African Americans are about twice as likely as white Americans to develop multiple myeloma and its precursor condition, MGUS, yet remain significantly underrepresented in research and clinical trials," says Bhasin. "This is the first and largest study of how African genetic ancestry relates to the bone marrow immune environment in myeloma."
A distinct immune landscape
Multiple myeloma is a cancer of plasma cells that develops in the bone marrow. Black people in the United States are about twice as likely as white people to develop the disease and its precursor condition, monoclonal gammopathy of undetermined significance, or MGUS. They also tend to be diagnosed at younger ages. The reasons are not fully understood and likely include biological, environmental and socioeconomic factors.
The team used the Multiple Myeloma Research Foundation's Immune Atlas and CoMMpass study to examine individual immune cells along with tumor and clinical information. The researchers measured genetic ancestry directly rather than relying only on self-reported race.
"The Immune Atlas allowed us to examine individual immune cells in unprecedented detail, while CoMMpass provided the context needed to understand how those immune features relate to ancestry," says George J. Mulligan, PhD, chief scientific officer of the MMRF and a co-senior author of the study. "Together, those resources enabled discoveries that would not have been possible just a few years ago."
Patients with higher African ancestry had more mature T cells equipped to kill abnormal cells, including a rare type of CD4 T cell. CD4 T cells are usually known for helping coordinate an immune response, but these cells carried molecules that can directly attack tumor cells.
They also had more adaptive natural killer cells, another specialized group of immune cells with tumor-killing features.
"To our surprise, we also saw less inflammation in the myeloid compartment," says Bhasin. "Studies in other cancers have generally reported more inflammation in patients of African ancestry, so this was unexpected."
Independent studies reach a similar conclusion
The major patterns were confirmed in separate Mayo Clinic patient groups using different technologies. Additional data from the MMRF CoMMpass study also showed reduced inflammatory activity in myeloma cells from patients with higher African genetic ancestry.
A companion study led by Mayo Clinic and published simultaneously in Blood examined immune patterns among self-identified Black and white patients across the spectrum of plasma cell disorders, including MGUS and multiple myeloma. While the Winship-led study focused on genetic ancestry in multiple myeloma, the Mayo-led study primarily examined self-identified race in a separate patient group. Race and genetic ancestry are related but are not interchangeable. The two studies used different patient groups and approaches but reached similar conclusions, strengthening confidence in the findings. Bhasin and William C. Pilcher are coauthors of both studies.
Questions for future treatment research
The study does not show that these immune differences cause multiple myeloma or explain differences in who develops the disease. It also does not predict how an individual patient will respond to treatment. Instead, it gives researchers new immune cells and pathways to investigate.
According to Bhasin, the findings could raise important questions about immune-based treatments. Adaptive natural killer cells found more often in patients with higher African ancestry had less CD38 on their surface. Researchers now want to learn whether that difference affects how those cells respond to CD38-targeted treatment. The idea has not yet been tested in patients.
Sagar Lonial, MD, FACP, FASCO
Sagar Lonial, MD, FACP, FASCO, chief medical officer of Winship Cancer Institute of Emory University and professor and chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, says the findings add important clinical context to researchers’ understanding of multiple myeloma.
“This study is a welcome addition to our understanding of biological differences among patients who have not always been adequately represented in large clinical trials. Our group and others have shown that disparities in multiple myeloma outcomes diminish when patients have equal access to care. These findings identify biological differences that could help inform how immune-based therapies are studied and used, particularly in populations that have not always had equitable access to care.”
Bhasin concludes, "Understanding each patient's immune environment may help us better match treatments to their biology. This is an important hypothesis that we now need to test."
Next steps
The research grew from a myeloma immune atlas published in Nature Cancer that linked immune patterns in the bone marrow with disease progression and outcomes. The new analysis focused on patients of African ancestry, a population disproportionately affected by myeloma but historically underrepresented in research.
Next, researchers plan to follow patients from MGUS through active myeloma to learn how immune cells change over time. They also hope to study healthy bone marrow and gather more information about social and environmental factors, other health conditions and infection history.
A broad collaboration
William C. Pilcher of Emory and Georgia Tech and Hongwei Tang of Mayo Clinic are co-first authors. Bhasin, George J. Mulligan of the MMRF and Linda B. Baughn of Mayo Clinic are senior authors.
The research was made possible by the MMRF CoMMpass study and the Immune Atlas Consortium. The CoMMpass team was led by Sagar Lonial, MD, FACP, FASCO. At Winship and Emory, Lonial, Ajay K. Nooka, MD, MPH, and Nishi Shah, MD, contributed clinical expertise. Researchers from several other cancer centers and universities also made important contributions to the study.